Stryker (SYK) Cash from Investing Activities (2009 - 2026)
Stryker's (SYK) quarterly Cash from Investing Activities came in at -$185.0 million in Q1 2026, up 95.53% year-on-year from -$94.6 million in Q1 2025, and up 39.34% on a QoQ basis from -$305.0 million in Q4 2025.
Stryker (SYK) Cash from Investing Activities (2009 - 2026) Analysis & Trends
Stryker (SYK) has 18 years of Cash from Investing Activities data on file, last reported at -$185.0 million in Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 95.53% year-over-year to -$185.0 million in Q1 2026; TTM through Mar 2026 was -$915.0 million, a 86.4% increase from a year earlier, with the FY2025 full-year figure at -$4.9 billion, down 62.2% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$185.0 million, up from -$305.0 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for SYK reached as high as $72.0 million in Q3 2022 and fell as low as -$4.1 billion in Q1 2025.
- Historically, Cash from Investing Activities has averaged -$702.2 million across 5 years, with a median of -$185.0 million in 2026.
- On a YoY basis, Cash from Investing Activities climbed as much as 129.15% in 2022 and fell as far as 2693.75% in 2022.
- Year by year, Cash from Investing Activities stood at -$162.0 million in 2022, then rose by 6.17% to -$152.0 million in 2023, then plunged by 99.34% to -$303.0 million in 2024, then declined by 0.66% to -$305.0 million in 2025, then surged by 39.34% to -$185.0 million in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$185.0 million in Q1 2026, -$305.0 million in Q4 2025, and -$321.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -475.32 Mn |
| 10 | Steris | 21.47 Bn | 21.03 Bn | 697.10 Mn | -217.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -185.00 Mn |
| Mar 31, 2026 | -185.00 Mn |
| Dec 31, 2025 | -305.00 Mn |
| Dec 31, 2025 | -305.00 Mn |
| Sep 30, 2025 | -321.00 Mn |
| Sep 30, 2025 | -321.00 Mn |
| Jun 30, 2025 | -104.00 Mn |
| Jun 30, 2025 | -104.00 Mn |
| Mar 31, 2025 | -4.14 Bn |
| Mar 31, 2025 | -4.14 Bn |
| Dec 31, 2024 | -303.00 Mn |
| Dec 31, 2024 | -303.00 Mn |
| Sep 30, 2024 | -2.17 Bn |
| Sep 30, 2024 | -2.17 Bn |
| Jun 30, 2024 | -117.00 Mn |
| Jun 30, 2024 | -117.00 Mn |
| Mar 31, 2024 | -408.00 Mn |
| Mar 31, 2024 | -408.00 Mn |
| Dec 31, 2023 | -152.00 Mn |
| Dec 31, 2023 | -152.00 Mn |